Champions Oncology Returns to Positive EBITDA as Data Business Resets Around a Broader Customer Base
Record revenue and four straight quarters of adjusted EBITDA mask a strategic pivot in the data licensing business and mounting Corellia optionality.
CSBR · Earnings Call · 2026-07-27
Discipline Pays Off
When Champions Oncology reported its fiscal 2026 year-end on July 27, the headline was a record top line and a return to consistent profitability. CEO Rob Brainin led with exactly that: “we delivered record annual revenue and met our commitment to full year positive adjusted EBITDA, including positive adjusted EBITDA in each of the 4 quarters on its own” — Robert Brainin, CEO · 2026-07-27. That string of four positive quarters is the first since fiscal 2022, and it came without material headcount additions — a sign that the operating leverage the company has been pointing to is finally showing up in the numbers. Total revenue reached $59.4 million, driven by 12% growth in the core core study services business, which posted its strongest year in company history. “It's still early for this business, and I expect revenue to continue to fluctuate in the near term, but the strategic logic behind it and the long-term opportunity as AI becomes more central to drug discovery only gets stronger.” — Robert Brainin, CEO · 2026-07-27 The data platform strategy is the one place where management is willing to trade short-term revenue for a longer-term competitive position.The Data Reset
No area of the business was more divergent than data licensing. Revenue fell from $4.7 million to $0.8 million, but management argues the comparison is misleading. The prior year included a single large transaction that didn't recur, while fiscal 2026 saw a deliberate push to broaden the customer base through smaller agreements. Brainin framed it bluntly: “Some of what we had expected to recognize in Q4, including revenue tied to the larger agreement we've discussed previously, shifted into the first quarter of fiscal 2027.” — Robert Brainin, CEO · 2026-07-27 The shift was purely timing, not demand destruction. In fact, the data business expanded its customer roster meaningfully, even if the dollar figure was fleeting. This is not the first time management has asked investors to look past quarterly data noise. On the December 2025 call, Brainin said, “We're definitely feeling good about the -- what we call OpGen, the opportunity generations we're seeing” — Robert Brainin, Chief Executive Officer · 2025-12-15. And on the September 2025 call, he was honest about the uncertainty: “It's still early, and it's premature to predict the exact size and success of this opportunity.” — Robert Brainin · 2025-09-15 The company is now living that reality — early revenue is lumpy, but the pipeline of both small and larger licensing opportunities is the real prize.The margin story is a core part of the thesis. CFO David Miller highlighted the 51% gross margin versus 41% a year ago, driven by the in-housing of radiopharmaceutical work. On the full-year basis, gross margin ticked up to 48% from 46%, even with the drag from lower-margin data revenue. As the radioligand platform scales, the incremental economics should only improve. Total revenue rose 12% in services while the cost base stayed flat, a clear sign of operating leverage.Fourth quarter gross margin improved to 51% compared to 41% in the prior year quarter. That improvement reflected continued cost discipline and importantly, a meaningful reduction in outsourced radiopharmaceutical costs as we've continued transitioning that work in-house.